What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?
Chemokine receptors are essential for human immunodeficiency virus (HIV) cell entry. CXCR4 and CCR5 are the two most relevant receptors and by inhibition of each of them a delayed onset of disease could be achieved. As both receptors are used at different stages of disease due to the domination of different HIV strains, a dual blockage of CXCR4 and CCR5 could be highly valuable for inhibiting viral transmission and replication.
Jülg
B
B
Department of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany.
Goebel
F D
FD
D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019718:Receptors, CXCR4; D019707:Receptors, Chemokine